Entera Bio Ltd

Stock Chart, Company Information, and Scan Results

$3.28(as of Nov 19, 4:00 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Entera Bio Ltd Company Information, Fundamentals, and Technical Indicators

Stock Price$3.28
Ticker SymbolENTX
ExchangeNasdaq
SectorHealthcare
IndustryBiotechnology
Employees27
CountyUSA
Market Cap$567.7M

Entera Bio Ltd., a clinical stage company, engages in the development of oral peptides and protein replacement therapies in Israel and internationally. It develops EB613, an oral teriparatide, which completed the Phase II clinical trial for the treatment of osteoporosis and Phase I clinical trial for the treatment of stress fractures. The company is also involved in the development of EB612, a tablet peptide replacement therapy, which is in Phase I clinical trial for the treatment of hypoparathyroidism; EB618, a GLP-1/glucagon dual agonist peptide, which is in Phase I clinical trial for the treatment of obesity, metabolic, and fibrotic disorders; and GLP-2 which is in Phase I clinical trial for the treatment of short bowel syndrome and disorders related to mucosal inflammation and nutrient malabsorption. It has a collaboration agreement with OPKO Biologics, Inc for the preclinical and clinical development of LA-PTH and oral dual agonist GLP-1/glucagon peptide. The company was incorporated in 2009 and is based in Jerusalem, Israel.

Entera Bio Ltd In Our Stock Scanner

As of Nov 19, 2026
As of ---

Join Our Free Email List

Get emails from us about ways to potentially make money in the stock market.